Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Hygeia Hospital- Hygeia Diagnostic & Therapeutic Center of Athens

Research site

Greece Erythrou Stavrou 4, 15124 Athens, Greece

  • Dyslipidaemia · Hormone-refractory prostate cancer · Prostate cancer
  • Adult patients

About Specializations

Hygeia Hospital- Hygeia Diagnostic & Therapeutic Center of Athens in Athens, Greece specialises in clinical trials of conditions such as Dyslipidaemia, Hormone-refractory prostate cancer, Prostate cancer, Prostate cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, with a particular focus on Metastatic Castration Resistant Prostate Cancer (mCRPC). This area of study is crucial for developing new therapeutic strategies to improve patient outcomes.

  • Advanced Prostate Cancer Treatments
  • Survival Rate Enhancement
  • Combination Therapy Efficacy

Through rigorous clinical trials, the center is pioneering the use of novel drug combinations, such as capivasertib with docetaxel, to enhance overall survival rates in patients with mCRPC.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Erythrou Stavrou 415124 AthensGreece
Open in maps ↗
Recruiting now
no trials
Conditions studied
4

More sites in AthensGreece

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Condition
Type of trial
Recruitment status
Quick filters

2 clinical trials

Dyslipidaemia

Not recruiting

Study Comparing Rosuvastatin and Fenofibrate with Pravastatin and Fenofibrate for Patients with Mixed Dyslipidemia at High Risk of Heart Disease

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Fenofibrate
  • Sponsor:Laboratoires S.M.B.

Hormone-refractory prostate cancer+2

Not recruiting

Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.